SELLAS Q3 update: REGAL topline still pending this month, SLS009 enrollment accelerates to 40 patients

What happened

SELLAS reported Q3 2026 results with no new efficacy data, but management reiterated that topline results from the Phase 3 REGAL trial will be reported this month following the 80th event. The company also disclosed that enrollment in the Phase 2 SLS009 first-line AML trial has risen to 40 patients, up from 28 reported in early August, with preliminary topline data still expected in Q4 2026. Cash declined modestly to $134.7 million from $138.3 million at the end of Q2, still ample to fund operations through the upcoming catalysts. The DeepValue report had flagged the lack of an 80th-event announcement by early November as a warning sign, but this release suggests the event has likely occurred or is imminent. While the update marginally reduces timing risk on both programs, it does not alter the core issue: the stock remains priced for a positive REGAL outcome that has not yet been demonstrated.

Implication

Investors should treat this as a routine progress report rather than a thesis-changing event. The acceleration in SLS009 enrollment from 28 to 40 patients is constructive and supports the Q4 2026 data timeline, but SLS009 alone cannot justify the current valuation. The explicit statement that REGAL topline will be reported this month reduces near-term timing uncertainty, yet the absence of an actual announcement means the binary risk persists. Cash remains sufficient, and no ATM usage was indicated, which is a positive. However, with shares trading at roughly $11 and a market cap near $2 billion against no revenue, the risk/reward is still unfavorable for new longs. Maintaining a cautious posture or waiting for a better entry near $8 or below remains prudent.

Thesis delta

The core sell thesis is unchanged: the stock remains priced for positive REGAL data before it exists. However, the Q3 update slightly reduces timing risk, as management now explicitly guides REGAL topline this month and SLS009 enrollment accelerated to 40, versus 28 previously. This warrants moving from 'potential sell' to a more neutral 'watchful hold' pending the actual data, but no new evidence supports buying at current levels.